Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.57 |
| ▸ | BACE1 | P56817 | 10/20 | 0.57 |
| ▸ | BCHE | P06276 | 8/20 | 0.57 |
| ▸ | CARM1 | Q86X55 | 5/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 5/20 | 0.51 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.51 |
| ▸ | FPR3 | P25089 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20492779 | 0.86 | CARM1 (0.68) | ACHEBACE1BCHECARM1PRMT6 | |
| SCHEMBL5011629 | 0.83 | CARM1 (0.48) | ACHEBACE1BCHECARM1PRMT6 | |
| SCHEMBL16538645 | 0.80 | HRH3 (0.63) | ACHEBACE1BCHECARM1PRMT6 | |
| SCHEMBL6245902 | 0.79 | CARM1 (0.44) | ACHEBACE1BCHECARM1PRMT6 | |
| SCHEMBL5016061 | 0.78 | CARM1 (0.54) | ACHEBACE1BCHECARM1PRMT6 | |
| SCHEMBL1241255 | 0.75 | RAB9A (0.58) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL5014997 | 0.75 | TP53 (0.43) | ACHEBACE1BCHECARM1PRMT6 | |
| SCHEMBL3318786 | 0.75 | ROCK1 (0.45) | CARM1PRMT6PRMT8 | |
| SCHEMBL16055288 | 0.75 | ACHE (0.85) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL23560251 | 0.74 | CARM1 (0.36) | BACE1CARM1PRMT6PRMT8FPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076762-A1 | Novel 4-Aminopiperidine Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-03-27 | — | — | US | disclosed |
| EP-1824822-A2 | NOVEL 4-AMINOPIPERIDINE DERIVATIVES AS PLASMEPSIN II INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006056930-A2 | NOVEL 4 -AMINOPIPERIDINE DERIVATIVES AS PLASMEPSIN II INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076762-A1 | Novel 4-Aminopiperidine Derivatives | METAP1, DNPEP, PEPD | ACHE 119/4885BACE1 191/4885BCHE 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.